HoxD10 gene delivery using adenovirus/adeno-associate hybrid virus inhibits the proliferation and tumorigenicity of GH4 pituitary lactotrope tumor cells

Biochemical and Biophysical Research Communications

Volumn 371, Issue 3, 2008, Pages 371-374

  Cho, Mi Ae ^a,b   Yashar, Parham ^c,d   Kim, Suk Kyoung ^a   Noh, Taewoong ^a   Gillam, Mary P ^c   Lee, Eun Jig ^a,c   Jameson, J Larry ^c  

^a Division of Endocrinology   (South Korea)

^b Dong Rae Bongseng Hospital   (South Korea)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adenovirus adeno associate virus hybrid vector; Angiogenesis; Cyclin D2; Fibroblast growth factor 2; GH4 lactotrope tumor; HoxD10

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CYCLIN D2; FIBROBLAST GROWTH FACTOR 2; PARVOVIRUS VECTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXD10;

ANIMAL CELL; ARTICLE; BETA GALACTOSIDASE GENE; CANCER GENE THERAPY; CANCER INHIBITION; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; GENE; GROWTH INHIBITION; HOXD10 GENE; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IN VITRO STUDY; MITOSIS INHIBITION; NONHUMAN; NONVIRAL GENE THERAPY; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION; RAT; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; CELL PROLIFERATION; CYCLINS; DEPENDOVIRUS; FIBROBLAST GROWTH FACTOR 2; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HOMEODOMAIN PROTEINS; MICE; PITUITARY NEOPLASMS; PROLACTINOMA; RATS; TRANSCRIPTION FACTORS;

MUS MUSCULUS; RATTUS;

EID: 43749120479     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.04.085     Document Type: Article

References (30)

1. Daniels G., and Martin J. Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus. In: Isselbacher K., Braunwald E., Wilson J., Martin J., and Kasper D. (Eds). Harrison's Principles of Internal Medicine (1995), McGraw-Hill, New York 1891-1918
2. Ciccarelli A., Daly A.F., and Beckers A. The epidemiology of prolactinomas. Pituitary 8 (2005) 3-6
3. Schlechte J.A. Long-term management of prolactinomas. J. Clin. Endocrinol. Metab. 92 (2007) 2861-2865
4. Molitch M.E. Pharmacologic resistance in prolactinoma patients. Pituitary 8 (2005) 43-52
5. Yildiz F., Zorlu F., Erbas T., and Atahan L. Radiotherapy in the management of giant pituitary adenomas. Radiother. Oncol. 52 (1999) 233-237
6. de la Torre N.G., Turner H.E., and Wass J.A. Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour. Pituitary 8 (2005) 17-23
7. de la Torre N.G., Wass J.A., and Turner H.E. Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas. Front. Horm. Res. 32 (2004) 133-145
8. Turner H.E., Harris A.L., Melmed S., and Wass J.A. Angiogenesis in endocrine tumors. Endocr. Rev. 24 (2003) 600-632
9. Monnet F., Elias K.A., Fagin K., Neill A., Goldsmith P., and Weiner R.I. Formation of a direct arterial blood supply to the anterior pituitary gland following complete or partial interruption of the hypophyseal portal vessels. Neuroendocrinology 39 (1984) 251-255
10. Myers C., Charboneau A., Cheung I., Hanks D., and Boudreau N. Sustained expression of homeobox D10 inhibits angiogenesis. Am. J. Pathol. 161 (2002) 2099-2109
11. Carrio M., Arderiu G., Myers C., and Boudreau N.J. Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. Cancer Res. 65 (2005) 7177-7185
12. Browne M., Stellmach V., Cornwell M., Chung C., Doll J.A., Lee E.J., Jameson J.L., Reynolds M., Superina R.A., Abramson L.P., and Crawford S.E. Gene transfer of pigment epithelium-derived factor suppresses tumor growth and angiogenesis in a hepatoblastoma xenograft model. Pediatr. Res. 60 (2006) 282-287
13. Lee E.J., Anderson L.M., Thimmapaya B., and Jameson J.L. Targeted expression of toxic genes directed by pituitary hormone promoters: a potential strategy for adenovirus-mediated gene therapy of pituitary tumors. J. Clin. Endocrinol. Metab. 84 (1999) 786-794
14. Lee E.J., Russell T., Hurley L., and Jameson J.L. Pituitary transcription factor-1 induces transient differentiation of adult hepatic stem cells into prolactin-producing cells in vivo. Mol. Endocrinol. 19 (2005) 964-971
15. Lee E.J., Duan W.R., Jakacka M., Gehm B.D., and Jameson J.L. Dominant negative ER induces apoptosis in GH(4) pituitary lactotrope cells and inhibits tumor growth in nude mice. Endocrinology 142 (2001) 3756-3763
16. Schmidt M., Fernandez de Mattos S., van der Horst A., Klompmaker R., Kops G.J., Lam E.W., Burgering B.M., and Medema R.H. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol. Cell. Biol. 22 (2002) 7842-7852
17. Ishikawa T., Lee E.J., and Jameson J.L. Nonhomologous end-joining ligation transfers DNA regulatory elements between cointroduced plasmids. Mol. Cell. Biol. 24 (2004) 8323-8331
18. Lee E.J., Jakacka M., Duan W.R., Chien P.Y., Martinson F., Gehm B.D., and Jameson J.L. Adenovirus-directed expression of dominant negative estrogen receptor induces apoptosis in breast cancer cells and regression of tumors in nude mice. Mol. Med. 7 (2001) 773-782
19. Lee E.J., and Jameson J.L. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. Hum. Gene. Ther. 13 (2002) 533-542
20. Lee E.J., and Jameson J.L. Gene therapy of pituitary diseases. J. Endocrinol. 185 (2005) 353-362
21. Lee E.J., Martinson F., Kotlar T., Thimmapaya B., and Jameson J.L. Adenovirus-mediated targeted expression of toxic genes to adrenocorticotropin-producing pituitary tumors using the proopiomelanocortin promoter. J. Clin. Endocrinol. Metab. 86 (2001) 3400-3409
22. Lee E.J., Thimmapaya B., and Jameson J.L. Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: implications for gene therapy. Neurosurgery 46 (2000) 1461-1468 (discussion 1468-1469)
23. Song Y.D., Lee E.J., Yashar P., Pfaff L.E., Kim S.Y., and Jameson J.L. Islet cell differentiation in liver by combinatorial expression of transcription factors neurogenin-3, BETA2, and RIPE3b1. Biochem. Biophys. Res. Commun. 354 (2007) 334-339
24. Basilico C., and Moscatelli D. The FGF family of growth factors and oncogenes. Adv. Cancer Res. 59 (1992) 115-165
25. Schwartz S.M., and Liaw L. Growth control and morphogenesis in the development and pathology of arteries. J. Cardiovasc. Pharmacol. 21 Suppl. 1 (1993) S31-S49
26. Asa S.L., Ramyar L., Murphy P.R., Li A.W., and Ezzat S. The endogenous fibroblast growth factor-2 antisense gene product regulates pituitary cell growth and hormone production. Mol. Endocrinol. 15 (2001) 589-599
27. Jackson T.A., Koterwas D.M., and Bradford A.P. Differential regulation of cell growth and gene expression by FGF-2 and FGF-4 in pituitary lactotroph GH4 cells. Mol. Cell. Endocrinol. 247 (2006) 183-191
28. Vlodavsky I., Folkman J., Sullivan R., Fridman R., Ishai-Michaeli R., Sasse J., and Klagsbrun M. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci. USA 84 (1987) 2292-2296
29. Heaney A.P., Horwitz G.A., Wang Z., Singson R., and Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat. Med. 5 (1999) 1317-1321
30. Osborne J., Hu C., Hawley C., Underwood L.J., O'Brien T.J., and Baker V.V. Expression of HOXD10 gene in normal endometrium and endometrial adenocarcinoma. J. Soc. Gynecol. Invest. 5 (1998) 277-280